IL-2, pivotal for supporting T cell proliferation and survival, is often termed T cells' "third signal." Preliminary research has revealed that marrying radiotherapy with high-dose IL-2 produces a synergistic effect, enhancing the immune response in a murine adenocarcinoma model with low immunogenicity 187. This evidence concerns the gene IL2 and adenocarcinoma.